Trinity Capital Fuels Growth for Candel Therapeutics
Trinity Capital Inc. (NASDAQ: TRIN), a prominent alternative asset manager, has announced a substantial commitment of $130 million to Candel Therapeutics, Inc. (NASDAQ: CADL). This investment aims to bolster the development of innovative viral immunotherapies that empower patients in their fight against cancer. Candel Therapeutics is recognized for its groundbreaking approach in treating various forms of cancer, leveraging the body’s own immune response.
Innovative Approach to Cancer Treatment
The medical landscape is shifting as Candel Therapeutics focuses on off-the-shelf cancer treatments that motivate the patient's immune system. Their flagship therapies, CAN-2409 and CAN-3110, target solid tumors prevalent in prostate, pancreatic, lung, and brain cancers. The company has achieved notable FDA designations, including Regenerative Medicine Advanced Therapy Designation (RMAT) for localized prostate cancer. These key designations help streamline the development process, ensuring timely access for patients needing innovative therapies.
Candel's Commitment to Transforming Oncology
Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, expressed pride in partnering with Candel, emphasizing the increasing demand for revolutionary cancer therapies. He highlighted how compelling clinical evidence from Candel could potentially reshape treatment paradigms for those grappling with serious health conditions.
Investment to Propel Clinical Development
Trinity Capital's investment will specifically support Candel's clinical advancements concerning CAN-2409. This includes preparing for commercial launch activities pending regulatory approval. This partnership is described as a pivotal juncture for Candel by its President and CEO, Paul Peter Tak, MD, PhD, FMedSci. The funding is expected to enhance Candel’s ability to drive innovative therapies for early-stage localized prostate cancer, non-small cell lung cancer, and glioblastoma, demonstrating a strong commitment to advancing oncology.
About Trinity Capital Inc.
Trinity Capital Inc., a leader in alternative asset management, focuses on delivering consistent returns for investors by linking them to private credit markets. The company specializes in various lending verticals, such as Sponsor Finance, Equipment Finance, and Life Sciences. They have successfully deployed over $4.7 billion across more than 420 investments since 2008. With a dedicated team spread throughout the U.S. and Europe, Trinity Capital remains a trusted partner for innovative firms needing capital solutions.
About Candel Therapeutics
Candel Therapeutics is at the forefront of developing multimodal viral immunotherapies designed to generate a personalized systemic anti-tumor immune response for cancer patients. Their significant achievements, including successful phase 2 clinical trials for CAN-2409, validate their focus on providing effective and innovative cancer treatments. Ongoing efforts with CAN-3110 are proving promising as the company continues in phase 1b trials. Utilizing the enLIGHTEN™ Discovery Platform, Candel aims to explore and create novel viral immunotherapies for treating solid tumors efficiently.
Frequently Asked Questions
What is the purpose of Trinity Capital's $130 million investment?
The investment aims to support Candel Therapeutics in advancing its clinical development and commercialization strategies for its cancer treatments.
What therapies are being developed by Candel Therapeutics?
Candel is developing viral immunotherapies like CAN-2409 and CAN-3110, targeting prostate, pancreatic, lung, and brain cancers.
How has Candel Therapeutics been recognized by the FDA?
Candel Therapeutics has received multiple FDA designations, including RMAT and Fast Track Designations for its innovative cancer therapies.
What is the significance of this investment for Candel?
This investment enhances Candel's financial stability, accelerating its initiatives to bring innovative cancer therapies to market.
Where can I find more information about Candel Therapeutics?
To learn more about their therapies and clinical trials, you can visit Candel Therapeutics' official website.
